Navigation Links
Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN) ("CeNeS" or "the Company") the Cambridge-based biopharmaceutical company today announced that a paper published this week in CNS Drugs(1) further supports the hypothesis that a catechol-O-methyltransferase (COMT) inhibitor that acts in the brain would be a useful agent to address profound cognitive deficits in schizophrenia and bipolar disorder. CeNeS has an ongoing discovery programme to develop novel COMT inhibitors.

The paper reviews the preclinical and clinical data surrounding COMT and includes studies carried out by the world leading group based at the National Institute of Mental Health, Bethesda, Maryland, USA. The paper's authors collate recent developments in the analysis of the role of COMT genotypes and their involvement in cognitive deficits in schizophrenia and bipolar disorder. The paper supports the view that there is potential to use COMT inhibitors in ameliorating their cognitive deficits via an effect on prefrontal cortex brain function. As part of their conclusions the authors note, "The development of newer COMT inhibitors that can permeate the BBB (blood brain barrier) effectively and are devoid of serious adverse effects will allow expansion of the search for more specific, selective therapies for the treatment of cognitive disorders".

CeNeS has a leading position in the discovery of a novel series of COMT inhibitors with a programme currently focused on drugs for treatment of Parkinson's disease. In addition to this, the continuing progression of the scientific rationale for the potential use of COMT inhibitors in the treatment of schizophrenia and bipolar disorder places the CeNeS discovery programme in a good position in an exciting area of neuroscience.

Neil Clark, Chief Executive of CeNeS said: "CeNeS is excited about its discovery programme's potential to deliver improved drugs for the treatment of
'"/>




Page: 1 2 3 4

Related medicine technology :

1. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
2. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
3. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
4. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
5. Major Manufacturer of Unapproved and Adulterated Drugs
6. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
7. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
8. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
9. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
10. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
11. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
Post Your Comments:
(Date:7/27/2015)... July 20, 2015 ... the addition of the "Cardiometabolic Drug News ... Afrezza,s discounted pricing is in line with our ... to the product,s commercial appeal. However, contraindications, side ... from gaining a sizeable share of the fast-acting ...
(Date:7/27/2015)... N.H. , July 27, 2015  Linear ... incredibly intricate machines, requiring not only adequate space ... vaults for their operation. Inherent to the size ... a linear accelerator or the addition of a ... hospital. Suspending operations risks interruption of patient treatment: ...
(Date:7/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ) has ... Receptors Market: Global Industry Analysis, Size, Share, Growth, ... to their offering. The global ... assay type, therapeutic area, and geography. Based on ... into six major segments: cAMP assays, calcium level ...
Breaking Medicine Technology:Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3Accelerating the Design Process for Cancer Treatment Centers 2Accelerating the Design Process for Cancer Treatment Centers 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Pharma NV/SA, a rapidly growing pharmaceutical company specialising in ... Veeva CRM to support its salesforce in Belgium. Pharco ... application that was both pharma-specific and easily adaptable. The ... for the global pharma and biotech industry. ...
... New Zealand health technology company Medtech Global, ... collaborated to develop an electronic health information solution ... medical records of visiting international MedicAlert members in ... first" the long term vision for the solution ...
Cached Medicine Technology:Pharco Pharma NV/SA Leverages Advantages of Cloud Computing With the Implementation of Veeva CRM 2Pharco Pharma NV/SA Leverages Advantages of Cloud Computing With the Implementation of Veeva CRM 3Medtech and MedicAlert Create Global Connection for Rugby World Cup 2011 2Medtech and MedicAlert Create Global Connection for Rugby World Cup 2011 3
(Date:7/27/2015)... ... July 27, 2015 , ... ... One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... the first things FDA investigators will look at during an inspection. Yet, ...
(Date:7/27/2015)... ... 27, 2015 , ... On July 14, 2015, Harper’s Bazaar Magazine in an ... skin issues such as stretch marks , fine lines , and ... treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is ...
(Date:7/27/2015)... ... July 27, 2015 , ... North Central Surgical Center Hospital ... The center invites all those prospective joint-replacement patients, along with their friends and family ... month, with Monday classes (Aug 6, Sept 8 [Tue due to Labor Day], Oct ...
(Date:7/27/2015)... , ... July 27, 2015 , ... David Gilmour ... He will be performing for one additional night at each of his original four ... DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing program of ... its options. Already an industry leader because of its use of iPad technology ... latest successful trends in helping people to overcome addiction and live healthy, productive ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
... says more programs needed for transition to adult health care ... arthritis need more help and information when they approach adulthood ... new study shows. , The study, led by Peter Scal ... of adolescents with arthritis received counseling on issues such as ...
... Drain NEW YORK, Jan. 13 New York Blood ... City, Long Island, Hudson Valley and New Jersey) have ... demand for blood (needed for emergency care and surgery) ... donation have been below forecast. Blood supplies have ...
... Goldring smiles as she shows a visitor photos she,s taken ... The demonstration comes more than 20 years after Goldring, a ... colleagues began work on a "seeing machine" that can allow ... the Internet, view the face of a friend and much ...
... New Version Increases Physician AccessSUNNYVALE, Calif., Jan. 13 ... version of the Pathwork(R) Tissue of Origin Test ... (FFPE) tissue specimens. This molecular diagnostic test, which ... origins, is now available as a service through ...
... 13, 2009) The American Journal of Nursing ... healthcare publications of 2008 with an announcement today of ... 15 separate categories appear in the journal,s January issue. ... of controversial consumer health topics and nursing industry issues ...
... Fla., Jan. 13 Zassi Medical,Evolutions(R), a privately ... and development, today announced the launch of e-Zassi(TM) ... the medical,device industry by streamlining diligence, collaboration and ... an exclusive array of,intelligent Web-based applications. , ...
Cached Medicine News:Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 2Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 3Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 4Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 5Health News:MIT develops camera for the blind 2Health News:Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens 2Health News:Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens 3Health News:American Journal of Nursing announces 2008 Book of the Year Awards 2Health News:Zassi Medical Evolutions Launches New Online Company That Uses 'Business DNA' to Deliver Advanced Discovery, Collaboration, and Business Intelligence Tools to the Medical Device Industry 2Health News:Zassi Medical Evolutions Launches New Online Company That Uses 'Business DNA' to Deliver Advanced Discovery, Collaboration, and Business Intelligence Tools to the Medical Device Industry 3
... The SYNCHRON CX5-S workstation ... electrolyte testing, targeted to the ... than 200 samples per day. ... the CX5-S is easy to ...
... the high-volume lab, the SYNCHRON LX4201 simplifies ... up to 2,880 tests per hour. By ... SYNCHRON LX4201 with broad menu, speed and ... come to expect from Beckman Coulter-innovative, reliable ...
... It takes powerful technology to ... safety, and still lower costs. ... LX20 PRO, offering features that ... any other chemistry analyzer, including ...
... the power of the LX2000 Series ... resources without compromising testing quality.Plus, when ... LX20 PRO, you get advanced features ... other chemistry analyzer, including closed tube ...
Medicine Products: